Peptides for Primary Sclerosing Cholangitis: New Frontiers

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptide-based therapies are emerging as a promising area for Primary Sclerosing Cholangitis, aiming to modulate immune responses and reduce liver fibrosis. These novel interventions offer the potential to slow disease progression and improve outcomes in this chronic liver condition.

Peptides for Primary Sclerosing Cholangitis: A New Frontier in Treatment

Primary Sclerosing Cholangitis (PSC) is a rare, chronic, and progressive liver disease characterized by inflammation and scarring of the bile ducts, both inside and outside the liver. This scarring leads to narrowing of the ducts, obstructing bile flow, and eventually causing liver damage, cirrhosis, and liver failure. Currently, there is no disease-modifying treatment for PSC, and liver transplantation remains the only definitive therapy for advanced cases. However, emerging research into peptide-based therapies offers a glimmer of hope for new interventions that could slow disease progression and improve patient outcomes.

Peptide-Based Strategies for Primary Sclerosing Cholangitis

Peptides are being investigated for their potential to modulate immune responses, reduce fibrosis, and protect bile duct cells in PSC.

1. Immunomodulatory Peptides

• Targeting Autoimmune Pathways: PSC is considered an autoimmune disease, where the immune system mistakenly attacks the bile ducts. Immunomodulatory peptides can precisely target and re-educate the immune system, aiming to dampen the destructive autoimmune response without causing broad immunosuppression [7].
• pMHCII-based Nanomedicines: Similar to other autoimmune liver conditions, peptide-major histocompatibility complex class II (pMHCII)-based nanomedicines are being explored. These nanomedicines can present specific autoantigenic epitopes to immune cells, potentially inducing tolerance and preventing further damage to the bile ducts [7].

2. Anti-fibrotic Peptides

• B7-33: This single-chain insulin-like peptide is being investigated for its selective signaling profile that favors anti-fibrotic actions [6]. In PSC, where fibrosis is a central feature leading to bile duct strictures and cirrhosis, B7-33 could play a crucial role in preventing or reversing the scarring process.
• General Anti-fibrotic Mechanisms: Other peptides with general anti-fibrotic properties, such as BPC-157, which is known for its tissue-repairing and anti-inflammatory effects, could also be beneficial in mitigating the fibrotic progression in PSC [9, 10].

3. Novel Peptide Therapeutics

• Navacim Therapeutics: Preclinical studies have shown that Navacim therapeutics, a peptide-based approach, can effectively blunt autoimmune liver diseases, including PSC, without suppressing general immunity [11]. This targeted approach represents a significant advancement in treating autoimmune conditions.

Clinical Outlook and Practical Advice

The development of peptide-based therapies for Primary Sclerosing Cholangitis is a critical area of research, as current treatment options are limited. These novel approaches offer the potential to address the underlying pathology of PSC more effectively, moving beyond symptomatic management towards disease modification.

Practical Takeaway

If you have been diagnosed with Primary Sclerosing Cholangitis, it is essential to work closely with your hepatologist to manage your condition and monitor for complications. While research into peptide therapies is ongoing, staying informed about clinical trials and discussing these advancements with your doctor can help you explore all potential options for managing your disease and improving your long-term outlook.

References

[1] Vesterhus, M., et al. (2020). Emerging therapies in primary sclerosing cholangitis. Journal of Hepatology, 73(1), 187-200. https://pmc.ncbi.nlm.nih.gov/articles/PMC7242240/
[2] Mayo Clinic. (2025). Primary sclerosing cholangitis (PSC) - Diagnosis and treatment. https://www.mayoclinic.org/diseases-conditions/primary-sclerosing-cholangitis/diagnosis-treatment/drc-20355802
[3] UC Davis Health. (2025). New trial at UC Davis Health shows promising results for rare liver disease. https://health.ucdavis.edu/news/headlines/new-trial-at-uc-davis-health-shows-promising-results-for-rare-liver-disease/2025/12
[4] AASLD. (2025). Primary Sclerosing Cholangitis Management Tips and Tricks. https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/primary-sclerosing-cholangitis-management-tips-and
[5] Mousavere, I., et al. (2023). An overview of recent treatment options for primary sclerosing cholangitis. World Journal of Gastroenterology, 29(43), 6079-6092. https://pmc.ncbi.nlm.nih.gov/articles/PMC10662072/
[6] Grantome. (n.d.). Anti-fibrotic therapy for primary sclerosing cholangitis. https://grantome.com/grant/NIH/R43-DK122874-01
[7] Gu, D., et al. (2026). Peptide-Based Therapeutics in Autoimmune Diseases. International Journal of Molecular Sciences, 27(1), 3. https://www.mdpi.com/2673-5261/7/1/3
[8] Chatterjee, D., et al. (2024). Immunomodulatory peptides: new therapeutic horizons for autoimmune diseases. Frontiers in Immunology, 15, 11695410. https://pmc.ncbi.nlm.nih.gov/articles/PMC11695410/
[9] Chang, C. H., et al. (2014). Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules, 19(11), 19066-19077. https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/
[10] Beverly Hills Concierge Doctor. (n.d.). BPC-157 Peptide Therapy. https://beverlyhillsconciergedoctor.com/anti-aging-wellness/peptide-therapy/bpc-157/
[11] Parvus Therapeutics. (2019). Parvus Therapeutics Publication of Preclinical Proof-of-Concept Research That Underlies the Development of Navacim Therapeutics for the Treatment of Autoimmune Liver Diseases. https://parvustx.com/parvus-therapeutics-publication-of-preclinical-proof-of-concept-research-that-underlies-the-development-of-navacim-therapeutics-for-the-treatment-of-autoimmune-liver-diseases/